Figure 6.

DCs infected with VSV carrying a native tumour antigen mediate tumor protection. Mice were challenged with 10⁶ B16-OVA cells i.v., and treated with PBS or immunized with DC-VSV/hDCT. Eleven days after immunization, mice were killed and spleens and lungs were collected. (a) Tumor nodules on lung surfaces were counted using a dissecting microscope (significantly greater tumor burden in PBS-treated compared to DC-VSV/MT (**P < 0.01) and DC-VSV/hDCT (**P < 0.001); *P < 0.05, significantly different tumor burdens between DC-VSV/MT and DC-VSV/hDCT). (b) IFNγ production by splenic NK cells was measured after in vitro culture without stimulation (*P < 0.05 compared to PBS-treated). (c) CD8⁺ T cells were restimulated with SVYVYQGL peptide in vitro and IFNγ production was measured (*P < 0.05 compared to PBS-treated). DC, dendritic cell; IFN, interferon; OVA, ovalbumin; PBS, phosphate-buffered saline; VSV, vesicular stomatitis virus.